Don’t let the allocation process endlessly drag on and impede or undermine the formulation an…
Should publicly held, early stage biotechs issue more shares or partner with Big Pharma?
According to “Health, United States, 2015,” a report published by the U.S. Department of He…
Performance metrics related to improvement or growth demonstrate the most positive relationship…
With the right brand-value metrics and framework, managements can allocate marketing resources …
Buyback ROI, a tool first introduced on CFO.com, can be used by executives and investors to det…
Buybacks can be an important tool in the corporate finance toolbox, but unfortunately the buyba…
To drive shareholder returns in health care, CFOs should stress financial policies that build f…
In many casual conversations with CFOs across a wide variety of companies and industries, we ha…
In this guide, we explain the nature of share buybacks, why they’re done, and how their retur…
Although high debt levels are touted to be shareholder-friendly, highly levered companies do no…
Major capital investment decisions are typically evaluated by comparing the value of the cash t…
ABOUT FORTUNA ADVISORS